Publicacións en colaboración con investigadores/as de University of Texas Health Science Center at San Antonio (1)

2022

  1. Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial

    Dermatologic Therapy, Vol. 35, Núm. 3